Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation

被引：0
|
作者：
Geeta Hampson
机构：
[1] Guy’s and St Thomas’ NHS Foundation Trust,Department of Chemical Pathology/Metabolic Bone Clinic
来源：
Calcified Tissue International | 2011年 / 88卷
关键词：
Osteoporosis; Bone Formation; Bisphosphonates; Teriparatide; Postmenopausal Osteoporosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures
    Andreassen, TT
    Ejersted, C
    Oxlund, H
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (06) : 960 - 968
  • [42] Association between circulating fibroblast growth factor-23 and age-related cardiovascular-renal parameters in a healthy Chinese population
    Wang, Nan
    Bai, Xiaojuan
    Jin, Bo
    Han, Wen
    Sun, Xuefeng
    Chen, Xiangmei
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2017, 17 (08) : 1221 - 1231
  • [43] Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - Results from a placebo-controlled randomized trial.
    Roe, EB
    Sanchez, SD
    del Puerto, GA
    Pierini, E
    Bacchetti, P
    Cann, CE
    Arnaud, CD
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S137 - S137
  • [44] The bone is the major source of high circulating intact fibroblast growth factor-23 in acute murine polymicrobial sepsis induced by cecum ligation puncture
    Bayer, Jessica
    Vaghela, Ravikumar
    Drechsler, Susanne
    Osuchowski, Marcin F.
    Erben, Reinhold G.
    Andrukhova, Olena
    PLOS ONE, 2021, 16 (05):
  • [45] The effect of parathyroid hormone (1–84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis
    J. Pepe
    C. Cipriani
    F. P. Cantatore
    A. Fabbri
    E. Pola
    V. Vinicola
    O. Raimo
    F. Biamonte
    R. Pascone
    C. Ferrara
    S. Minisola
    Journal of Endocrinological Investigation, 2017, 40 : 663 - 667
  • [46] Intermittent administration of human parathyroid hormone (1-34) increases new bone formation on the interface of hydroxyapatitecoated titanium rods implanted into ovariectomized rat femora
    Ohkawa, Yutaka
    Tokunaga, Kunihiko
    Endo, Naoto
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2008, 13 (06) : 533 - 542
  • [47] 25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population
    Jovanovich, Anna J.
    Chonchol, Michel
    Brady, Christopher B.
    Kaufman, James D.
    Kendrick, Jessica
    Cheung, Alfred K.
    Jablonski, Kristen L.
    CLINICAL NEPHROLOGY, 2014, 82 (05) : S1 - S4
  • [48] Serum Phosphorus, Parathyroid Hormone, and Serum Fibroblast Growth Factor-23 in Egyptian Patients Six Months after Undergoing Living-donor Kidney Transplantation
    Kamel, Mai Hamed
    Ahmed, Dina Hesham
    Mikhael, Emily Samir
    Abdalla, Mohamed Shehata
    Sadek, Khaled Marzouk
    ElNahid, Maggie Said
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2022, 33 (03) : 353 - 360
  • [49] INCREASED LEVELS OF SERUM PARATHYROID HORMONE AND FIBROBLAST GROWTH FACTOR-23 ARE THE MAIN FACTORS ASSOCIATED WITH THE PROGRESSION OF VASCULAR CALCIFICATION IN LONG-HOUR HEMODIALYSIS PATIENTS
    Jean, Guillaume
    Bresson, Eric
    Chazot, Charles
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 496 - 496
  • [50] High C-Terminal Fibroblast Growth Factor-23, Intact Parathyroid Hormone, and Interleukin-6 as Determinants of Valvular Calcification in Regular Hemodialysis Patients
    Kandarini, Yenny
    Mahadita, Gede Wira
    Herawati, Sianny
    Wibhuti, Ida Bagus Rangga
    Widiana, I. Gde Raka
    Ayu, Nyoman Paramita
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 4227 - 4236
12345